These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9551716)

  • 1. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
    Betancur C; Canton M; Burgos A; Labeeuw B; Gully D; Rostène W; Pélaprat D
    Eur J Pharmacol; 1998 Feb; 343(1):67-77. PubMed ID: 9551716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
    Gully D; Labeeuw B; Boigegrain R; Oury-Donat F; Bachy A; Poncelet M; Steinberg R; Suaud-Chagny MF; Santucci V; Vita N; Pecceu F; Labbé-Jullié C; Kitabgi P; Soubrié P; Le Fur G; Maffrand JP
    J Pharmacol Exp Ther; 1997 Feb; 280(2):802-12. PubMed ID: 9023294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
    Labbé-Jullié C; Botto JM; Mas MV; Chabry J; Mazella J; Vincent JP; Gully D; Maffrand JP; Kitabgi P
    Mol Pharmacol; 1995 May; 47(5):1050-6. PubMed ID: 7746272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.
    Betancur C; Canton M; Gully D; Vela G; Pélaprat D; Rostène W
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1450-8. PubMed ID: 7791120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area.
    Leonetti M; Brun P; Sotty F; Steinberg R; Soubrié P; Bert L; Renaud B; Suaud-Chagny MF
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):427-33. PubMed ID: 12070755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist.
    Brun P; Leonetti M; Sotty F; Steinberg R; Soubrié P; Renaud B; Suaud-Chagny MF
    J Neurochem; 2001 Jun; 77(6):1542-52. PubMed ID: 11413237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
    Binder EB; Kinkead B; Owens MJ; Kilts CD; Nemeroff CB
    J Neurosci; 2001 Jan; 21(2):601-8. PubMed ID: 11160439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists.
    Azzi M; Gully D; Heaulme M; Bérod A; Pélaprat D; Kitabgi P; Boigegrain R; Maffrand JP; LeFur G; Rostène W
    Eur J Pharmacol; 1994 Apr; 255(1-3):167-74. PubMed ID: 8026542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain.
    Schotte A; Leysen JE; Laduron PM
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Aug; 333(4):400-5. PubMed ID: 3022160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation by neurotensin of (3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices.
    Héaulme M; Leyris R; Soubrié P; Le Fur G
    Neuropeptides; 1998 Oct; 32(5):465-71. PubMed ID: 9845009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.
    Gully D; Canton M; Boigegrain R; Jeanjean F; Molimard JC; Poncelet M; Gueudet C; Heaulme M; Leyris R; Brouard A
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):65-9. PubMed ID: 8380498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells.
    Yamada M; Yamada M; Lombet A; Forgez P; Rostène W
    Life Sci; 1998; 62(23):PL 375-80. PubMed ID: 9627096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
    Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
    Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
    Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
    Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization.
    Panayi F; Colussi-Mas J; Lambás-Señas L; Renaud B; Scarna H; Bérod A
    Neuropsychopharmacology; 2005 May; 30(5):871-9. PubMed ID: 15637639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Neuropsychopharmacology; 2004 Dec; 29(12):2200-7. PubMed ID: 15328528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
    Belmeguenai A; Vaudry H; Leprince J; Vivet B; Cavelier F; Martinez J; Louiset E
    Neuroendocrinology; 2000 Dec; 72(6):379-91. PubMed ID: 11146421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Administration of Levocabastine, a NTS2 Receptor Antagonist, Modifies Na(+), K(+)-ATPase Properties.
    Gutnisky A; López Ordieres MG; Rodríguez de Lores Arnaiz G
    Neurochem Res; 2016 Jun; 41(6):1274-80. PubMed ID: 26738992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).
    Akunne HC; Demattos SB; Whetzel SZ; Wustrow DJ; Davis DM; Wise LD; Cody WL; Pugsley TA; Heffner TG
    Biochem Pharmacol; 1995 Apr; 49(8):1147-54. PubMed ID: 7748196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.